[
  {
    "cui": "C0949690",
    "cui_name": "Spondylarthritis",
    "incidence_per_100k": null,
    "prevalence_per_100k": 1200,
    "metric_type": "prevalence",
    "total_cases_per_year": 96000000,
    "confidence": 0.65,
    "is_subtype": false,
    "parent_disease": null,
    "reasoning": "Spondylarthritis group (ankylosing spondylitis, reactive arthritis, psoriatic arthritis with spondylitis, IBD-associated arthritis) reported as prevalence ~1.0-1.5% globally (1,000-15,000 per 100k), with 1.2% (~12 per 100k) as reasonable midpoint. Prevalence preferred over incidence for this chronic condition group. Significant geographic variation due to HLA-B27 distribution.",
    "data_quality": "moderate",
    "geographic_variation": "high",
    "year_specific": false,
    "data_year": null,
    "source": "van der Linden S et al. (2016). Ankylosing spondylitis and axial spondyloarthritis: clinical features and treatment. Nat Rev Dis Primers. 2:16008",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/27189985/",
    "source_type": "literature"
  }
]
